Kensey Nash Reports Fourth Quarter and Fiscal Year 20...(Ended June 30 Ended June 30 ....)

2008 2007 2008 2007

Revenues:

Net sales

Biomaterial

sales $13,330,890 $9,701,925 $47,538,923 $41,116,112

Endovascular

sales 1,637,713 805,574 6,221,942 3,786,257

Total net sales 14,968,603 10,507,499 53,760,865 44,902,369

Royalty income 7,003,252 6,471,459 26,030,032 24,592,076

Total revenues 21,971,855 16,978,958 79,790,897 69,494,445

Operating costs and

expenses:

Cost of products

sold 9,097,198 8,658,502 27,211,681 24,621,727

Research and

development 4,339,583 5,844,513 17,200,762 20,265,046

Sales and

marketing 4,232,527 3,269,628 14,747,333 12,524,501

General and

administrative 4,851,947 2,331,032 12,827,771 8,299,525

Loss on sale of

endovascular

assets 1,212,478 - 1,212,478 -

Total operating

costs and

expenses 23,733,733 20,103,675 73,200,025 65,710,799

(Loss) Income from

operations (1,761,878) (3,124,717) 6,590,872 3,783,646

Interest and other

(loss) income, net (263,568) 106,278 15,088 636,921

Pre-tax (loss) income (2,025,446) (3,018,439) 6,605,960 4,420,567

Income tax (benefit)

expense (930,480) (1,273,666) 1,816,179 787,416

Net (loss) income $(1,094,966) $(1,744,773) $4,789,781 $3,633,151

Basic (loss) earnings

per share $(0.09) $(0.15) $0.40 $0.31

Diluted (loss)

earnings per share $(0.09) $(0.15) $0.38
'/>"/>